These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 10662409)

  • 1. Counting and discounting gained life-years.
    Søgaard J; Gyrd-Hansen D
    Dev Health Econ Public Policy; 1998; 6():51-74. PubMed ID: 10662409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of screening for cancer in the Nordic countries on deaths, cost and quality of life up to the year 2017.
    Hristova L; Hakama M
    Acta Oncol; 1997; 36 Suppl 9():1-60. PubMed ID: 9143316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. On discounting of health gains from human papillomavirus vaccination: effects of different approaches.
    Westra TA; Parouty M; Brouwer WB; Beutels PH; Rogoza RM; Rozenbaum MH; Daemen T; Wilschut JC; Boersma C; Postma MJ
    Value Health; 2012 May; 15(3):562-7. PubMed ID: 22583467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On the discounting of gained life-years in cost-effectiveness analysis.
    Johannesson M
    Int J Technol Assess Health Care; 1992; 8(2):359-64. PubMed ID: 1628916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of a quality-controlled mammography screening program from the Swiss statutory health-care perspective: quantitative assessment of the most influential factors.
    Neeser K; Szucs T; Bulliard JL; Bachmann G; Schramm W
    Value Health; 2007; 10(1):42-53. PubMed ID: 17261115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mass screening on abdominal aortic aneurysm in men aged 60 to 65 years in The Netherlands. Impact on life expectancy and cost-effectiveness using a Markov model.
    Boll AP; Severens JL; Verbeek AL; van der Vliet JA
    Eur J Vasc Endovasc Surg; 2003 Jul; 26(1):74-80. PubMed ID: 12819652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.
    Armstrong EP
    J Manag Care Pharm; 2010 Apr; 16(3):217-30. PubMed ID: 20331326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of screening for anal squamous intraepithelial lesions and anal cancer in human immunodeficiency virus-negative homosexual and bisexual men.
    Goldie SJ; Kuntz KM; Weinstein MC; Freedberg KA; Palefsky JM
    Am J Med; 2000 Jun; 108(8):634-41. PubMed ID: 10856411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of screening for colorectal cancer in the general population.
    Frazier AL; Colditz GA; Fuchs CS; Kuntz KM
    JAMA; 2000 Oct; 284(15):1954-61. PubMed ID: 11035892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of cervical cancer screening: comparison of screening policies.
    van den Akker-van Marle ME; van Ballegooijen M; van Oortmarssen GJ; Boer R; Habbema JD
    J Natl Cancer Inst; 2002 Feb; 94(3):193-204. PubMed ID: 11830609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA.
    Palmer AJ; Valentine WJ; Chen R; Mehin N; Gabriel S; Bregman B; Rodby RA
    Nephrol Dial Transplant; 2008 Apr; 23(4):1216-23. PubMed ID: 18359872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The importance of age in screening for cancer.
    Law MR; Morris JK; Wald NJ
    J Med Screen; 1999; 6(1):16-20. PubMed ID: 10321365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Choice of Hemodialysis Access in Older Adults: A Cost-Effectiveness Analysis.
    Hall RK; Myers ER; Rosas SE; O'Hare AM; Colón-Emeric CS
    Clin J Am Soc Nephrol; 2017 Jun; 12(6):947-954. PubMed ID: 28522655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential gains in life expectancy by reducing inequality of lifespans in Denmark: an international comparison and cause-of-death analysis.
    Aburto JM; Wensink M; van Raalte A; Lindahl-Jacobsen R
    BMC Public Health; 2018 Jul; 18(1):831. PubMed ID: 29973183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of human papillomavirus vaccination in South Africa accounting for human immunodeficiency virus prevalence.
    Li X; Stander MP; Van Kriekinge G; Demarteau N
    BMC Infect Dis; 2015 Dec; 15():566. PubMed ID: 26652918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Multigene Test Could Cost-Effectively Help Extend Life Expectancy for Women at Risk of Hereditary Breast Cancer.
    Li Y; Arellano AR; Bare LA; Bender RA; Strom CM; Devlin JJ
    Value Health; 2017 Apr; 20(4):547-555. PubMed ID: 28407996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preventive health screenings and health consultations in primary care increase life expectancy without increasing costs.
    Rasmussen SR; Thomsen JL; Kilsmark J; Hvenegaard A; Engberg M; Lauritzen T; Søgaard J
    Scand J Public Health; 2007; 35(4):365-72. PubMed ID: 17786799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of HPV vaccination alongside cervical cancer screening programme in Slovenia.
    Obradovic M; Mrhar A; Kos M
    Eur J Public Health; 2010 Aug; 20(4):415-21. PubMed ID: 20624834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term benefit and cost-effectiveness analysis of screening for abdominal aortic aneurysms from a randomized controlled trial.
    Lindholt JS; Sørensen J; Søgaard R; Henneberg EW
    Br J Surg; 2010 Jun; 97(6):826-34. PubMed ID: 20473995
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.